Emmaus Life Sciences (OTCMKTS:EMMA) vs. Abpro (NASDAQ:ABP) Head-To-Head Review

Emmaus Life Sciences (OTCMKTS:EMMA) and Abpro (NASDAQ:ABP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Emmaus Life Sciences and Abpro, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emmaus Life Sciences	0	0	0	0	0.00
Abpro	1	1	0	0	1.50

Institutional & Insider Ownership

7.4% of Emmaus Life Sciences shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 35.0% of Emmaus Life Sciences shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Emmaus Life Sciences and Abpro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emmaus Life Sciences	-70.64%	N/A	-40.35%
Abpro	N/A	N/A	-344.76%

Valuation & Earnings

This table compares Emmaus Life Sciences and Abpro”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emmaus Life Sciences	$12.45 million	0.07	-$7.49 million	($0.13)	-0.10
Abpro	N/A	N/A	-$7.23 million	($4.23)	-0.12

Abpro has lower revenue, but higher earnings than Emmaus Life Sciences. Abpro is trading at a lower price-to-earnings ratio than Emmaus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Emmaus Life Sciences beats Abpro on 5 of the 9 factors compared between the two stocks.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

About Abpro

Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.